authors
-
Zbigniew Jabłonowski
- I Klinika Urologii Katedry Urologii Uniwersytetu Medycznego w Łodzi
keywords
-
prostate prostate cancer chemoprevention finasteride PCPT study
summary
- In Poland the amount of newly diagnosed prostate cancers increases systematically with the number of 7095 cases in 2005. It is
- estimated that 200 000 men are diagnosed with prostate cancer in the USA annually and about 90% of them receive treatment for
- it. The Prostate Cancer Prevention Trial (PCPT) was the first prospective, randomized, placebo-controlled clinical trial of prostate cancer
- chemoprevention. Initial results of the study showed a greater proportion and number of histologically high-grade carcinomas. A new
- analysis from the Prostate Cancer Prevention Trial shows that finasteride does not increase the risk for high-grade prostate cancer. The
- latest data from 2008 demonstrate that chemopreventive treatment with finasteride for 7 years decreases the incidence of prostate
- cancer by an estimated 30%, without increasing the incidence of high-grade tumours. The new analysis shows how small differences
- in biopsy sensitivity between the study arms could results in the apparent finasteride-assosiated increase in high-grades on biopsy
- that was reported in 2003. The findings of the PCPT seem to provide the foundation for the further studies on chemoprevention of
- prostate cancer.
references
- Sporn MB: New agents for chemoprevention of prostate cancer. Eur Urol 1999, 35, 420-423.
- Leach R, Pollock B, Basler J et al: Chemoprevention of prostate cancer. Focus on key opportunities and clinical trials. Urol Clin North Am. 2003, 30 (2), 227-237.
- Paradigm Shift in the Primary Prevention of Prostate Cancer, Reanalysis of the PCPT Data. A Report from the 103rd Annual Meeting of the American Urological Association Orlando/May 17-22, 2008, Medical Frontiers International.
- Redman MW, Tangen CM, Goodman PJ et al: Finasteride does not increase the risk of high-grade prostate cancer, a bias-adjusted modeling approach. Cancer Prev Res 2008, Online First 2008, 10.1158/1940-6207. CAPR-08-0092.
- Raporty Centrum Onkologii, http//85.128.14.124/krn
- Dobruch J, Borówka A, Antoniewicz AA, Chłosta P: Prostatektomia radykalna w Polsce. Urol Pol 2005, 58, 2, 108-111.
- Brawley OW, Barnes ST: Potential agents for prostate cancer chemoprevention. Epidemiol Rev 2001, 23, 1, 168-172.
- Wang J, Eltoum IE, Lamartiniere CA: Genistein chemoprevention of prostate cancer in TRAMP mice. J Carcinog 2007, 16, 6, 3.
- Bonovas S, Filioussi K, Sitaras NM: Statin use and the risk of prostate cancer, a metaanalysis of 6 randomized clinical trials and 13 observational studies. Int J Cancer 2008, 15, 123, 899-904.
- Tindall DJ, Rittmaster RS: The rationale for inhibiting 5 alpha-reductase isoenzymes in the prevention and treatment of prostate cancer. J Urol 2008, 179, 4, 1235-1242.
- Festuccia C, Gravina GL, Muzi P et al: Effects of dutasteride on prostate carcinoma primary cultures, a comparative study with finasteride and MK386. J Urol 2008, 180, 1, 367-372.
- McCrohan MA, Morrissey C, O’Keane C, et al: Effects of the dual 5 alpha-reductase inhibitor dutasteride on apoptosis in primary cultures of prostate cancer epithelial cells and cell lines. Cancer 2006, 106, 12, 2743-2752.
- Gomella LG: Chemoprevention using dutasteride, the REDUCE trial. Curr Opin Urol 2005, 15, 1, 29-32.
- Musquera M, Fleshner NE, Finelli A, Zlotta AR: The REDUCE trial, chemoprevention in prostate cancer using a dual 5alpha-reductase inhibitor, dutasteride. Expert Rev Anticancer Ther 2008, 8, 7, 1073-1079.
- Thompson IM, Goodman PJ, Tangen CM et al: The influence of finasteride on the development of prostate cancer. N Engl J Med 2003, 349, 215-224.
- Scardino PT: The prevention of prostate cancer-the dilemma continues. N Engl J Med 2003, 349, 297-299.
- Lucia MS, Darke AK, Goodman PJ et al: Pathologic characteristics of cancers detected in the prostate cancer prevention trial, implications for prostate cancer detection and chemoprevention. Cancer Prev Res 2008, Online First 2008, 10.1158/1940-6207.CAPR-08-0078.
- Logothetis CJ, Schellhammer PF: High-grade prostate cancer and the Prostate Cancer Prevention Trial. Cancer Prev Res 2008, Online First 2008, 10.1158/1940-6207.CAPR-08-0085.
- D’Amico AV, Barry MJ: Prostate cancer prevention and finasteride. J Urol 2006, 176, 5, 2010-2013.
- 12. Lucia MS, Epstein JL, Goodman PJ et al: Finasteride and high-grade prostate cancer in the Prostate Cancer Prevention Trial. J Natl Cancer Inst 2007, 99, 1375-1383.
- Walsh PC: Implications of the prostate cancer prevention trial, a decision analysis model of survival outcomes. J Urol 2005, 174, 1293-1294.
correspondence
Zbigniew Jabłonowski
I Klinika Urologii UM
ul. Żeromskiego 113
90-549 Łódź
tel. (042) 636 82 14
zby_szek@tlen.pl
|